# OpenAI Invests in Sam Altman's Brain Computer Interface Startup Merge Labs

**Source**: https://techcrunch.com/2026/01/15/openai-invests-in-sam-altmans-brain-computer-interface-startup-merge-labs/

**Date**: January 15, 2026

**Author**: Rebecca Bellan

**Keywords**: OpenAI, brain-computer interface, BCI, Merge Labs, Sam Altman, neurotechnology, AI investment, human augmentation

## Elevator pitch

OpenAI led a $250 million seed round for Merge Labs, Sam Altman's brain-computer interface startup focused on bridging biological and artificial intelligence, signaling strategic interest in neurotechnology as a complement to AI development.

## Takeaways

- Merge Labs raised $250 million in seed funding at an $850 million valuation, with OpenAI contributing the largest investment check
- The company's mission focuses on "bridging biological and artificial intelligence to maximize human ability" through brain-computer interface research
- OpenAI's investment demonstrates strategic diversification into neurotechnology as a potential complement to its core AI capabilities
- Sam Altman's involvement reflects continued interest in emerging technologies beyond his OpenAI leadership role
- The funding round signals growing investment momentum in brain-computer interfaces as frontier technology with both medical and enhancement applications

## Synthesis

TechCrunch's report on OpenAI's investment in Merge Labs reveals a significant strategic move that connects artificial intelligence development with brain-computer interface research. The $250 million seed round at an $850 million valuation represents substantial capital for a research-stage neurotechnology venture, and OpenAI's position as lead investor signals serious conviction in the intersection of AI and BCI technologies.

Merge Labs positions itself at the convergence point between biological and artificial intelligence. The stated mission—maximizing human ability through this convergence—suggests applications beyond current BCI use cases like medical treatment for paralysis or neurological conditions. The involvement of both Sam Altman personally and OpenAI institutionally hints at a vision where brain-computer interfaces could serve as input/output channels for AI systems, potentially enabling more direct human-AI interaction than current text and voice interfaces allow.

The investment timeline is notable. BCI technology remains largely experimental, with even leading companies like Neuralink facing long development cycles before widespread commercial deployment. OpenAI's willingness to make a significant seed-stage commitment suggests a long-term strategic view rather than expectation of near-term returns. This patience contrasts with the rapid deployment cycle of large language models and indicates that OpenAI leadership sees neurotechnology as a multi-year strategic bet.

The corporate governance implications deserve attention. Sam Altman simultaneously leads OpenAI and holds involvement with Merge Labs as a separate venture. OpenAI investing heavily in an Altman-affiliated company creates potential conflict-of-interest questions, though such arrangements are not unusual in Silicon Valley's interconnected investment ecosystem. The scale of the investment—$250 million seed round with OpenAI as lead—suggests this relationship was negotiated with full board awareness.

From a technology convergence perspective, the investment makes conceptual sense. If AI systems continue advancing toward more sophisticated reasoning and generation capabilities, the interface between humans and these systems becomes increasingly important. Current interfaces—keyboards, voice, screens—impose significant bandwidth constraints on human-AI communication. Brain-computer interfaces, if they mature sufficiently, could dramatically increase this bandwidth, enabling new forms of collaboration between human cognition and AI capabilities.

The broader industry context shows accelerating interest in neurotechnology investment. Multiple well-funded BCI companies now operate across medical and enhancement applications. OpenAI's entry as a major investor from the AI side of the industry validates the convergence thesis and may encourage further investment at the AI-neurotechnology intersection.
